ClinicalTrials.gg
CompletedNCT05882734Updated Sep 14, 2026

Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)

A Phase 1/2 interventional study of M1774 and Cemiplimab in Non-Small Cell Lung Cancer, sponsored by EMD Serono Research & Development Institute, Inc.. Completed at 54 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-14.

Sponsored by EMD Serono Research & Development Institute, Inc. (part of Merck KGaA, Darmstadt, Germany) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
61
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies testing cemiplimab in Carcinoma, Non-Small-Cell Lung — 18 open to participants now, 22 under way, 3 of them phase 3. cemiplimab · Carcinoma, Non-Small-Cell Lung.

Enrollment
15th of 29
61 · median 61
Started
2023
with 2 others
Phase 1/2
2 of 29
1 open now
Registered
11th of 29
by date
Lead sponsor
1 of 29
EMD Serono Research & Development Institute, Inc.

Among the 29 studies testing cemiplimab in Carcinoma, Non-Small-Cell Lung, this one is the 15th largest by enrollment, is one of 3 that started in 2023, is one of 2 in phase 1/2, and was the 11th registered.

Carcinoma, Non-Small-Cell Lung

7,624 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

18 of the 29 studies testing cemiplimab in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

13 more — sign in →

By country, each count listing its studies:

All 18 open studies →

About cemiplimab

cemiplimab: first FDA approval 2018 (LIBTAYO), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies testing cemiplimab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This is an Open-label, multicenter clinical study conducted in two Phases to establish the efficacy, safety, tolerability, and pharmacokinetics of the ataxia telangiectasia mutated and Rad3-related protein kinase (ATR) inhibitor Tuvusertib in Combination with Cemiplimab in Participants with Non-Squamous Non-Small Cell Lung Cancer (nsqNSCLC) that has Progressed on Prior Anti-PD-(L)1 and Platinum-based Therapies..

03

Conditions studied

  • Non-Small Cell Lung Cancer

Keywords

  • Ataxia telangiectasia mutated and Rad3-related protein kinase (ATR) inhibitor
  • Tuvusertib (M1774)
  • Non squamous Non small cell lung cancer
  • Cemiplimab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who are diagnosed with nsqNSCLC or cytologically confirmed
  • Participants with Radiologically confirmed/documented disease progression during or after the following systemic therapies (all required):

    • At most, 1 line of anti-PD-(L)1 therapy for locally advanced or disease. Rechallenge with the same anti-PD-(L)1 for disease considered sensitive to anti-PD-(L)1 therapy (e.g. after a treatment break) is considered 1 line
    • Platinum-based therapy for locally advanced or metastatic disease, given in combination or sequentially with anti-PD-(L)1 therapy. Participants who received platinum-based therapy meet this criterion if disease progression occurred within 6 months from the last dose that the participant received that therapy. No additional cytotoxic therapies after progression on platinum-based therapy are allowed
    • Prior best overall response of stable disease or better with anti-PD-(L)1 therapy
    • Disease progression must have occurred while the participant has been receiving anti-PD-(L)1 therapy or within 16 weeks of the last dose of anti-PD-(L)1 therapy
  • Participants with per v1.1
  • Participants with (ECOG) PS 0 or 1
  • Adequate hematological, hepatic, and renal function as defined in the protocol.
  • Phase 2a part only: central liquid analysis of tumor molecular alterations with an assay with appropriate regulatory status
  • Other protocol defined inclusion criteria could apply

Exclusion criteria

Exclusion Criteria:

  • Participants with tumors harboring actionable epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic aberrations. Participants with tumors with other actionable aberrations are eligible and allowed to have received up to 1 line of available targeted therapy
  • Participants with history of additional within 3 years before the date of enrollment. Exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or malignancy that in the opinion of the Investigator, with concurrence of the Sponsor's Medical Monitor, is considered cured with minimal risk of recurrence within 3 years
  • Participants with known , unless clinically stable
  • Participant with history of (noninfectious) pneumonitis that required systemic or current pneumonitis/interstitial lung disease
  • Other protocol defined exclusion criteria could apply
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
61 participants (actual)

Study arms

  • Experimental
    Dosing Regimen 1 (Phase 1b): M1774 + Cemiplimab

    Drug: M1774 · Drug: Cemiplimab

  • Experimental
    Dosing Regimen 2 (Phase 1b): M1774 + Cemiplimab

    Drug: M1774 · Drug: Cemiplimab

  • Experimental
    Stratum A (Phase 2a): Either Dosing Regimen 1 or 2 as finalized in Phase 1b

    Drug: M1774 · Drug: Cemiplimab

  • Experimental
    Stratum B (Phase 2a): Either Dosing Regimen 1 or 2 as finalized in Phase 1b

    Drug: M1774 · Drug: Cemiplimab

  • Experimental
    Stratum C (Phase 2a): Either Dosing Regimen 1 or 2 as finalized in Phase 1b

    Drug: M1774 · Drug: Cemiplimab

Interventions

  • DrugM1774

    In Phase 1b, M1774 will be administered as dosing regimen 1 or dosing regimen 2 until disease progression, death discontinuation criteria or any other reason. The selected dosing regimen of M1774 will be administered in all arms of Phase 2a.

    Also known as: Tuvusertib

  • Cemiplimab will be administered as an intravenous infusion every 3 weeks in all arms of Phase 1b and Phase 2a until disease progression, death discontinuation criteria or any other reason.

06

What researchers measure

Primary outcomes

  1. Phase 1b/Phase 2a: Confirmed Overall response (OR) According to Response Evaluation Criteria in Solid Tumor (RECIST) 1.1 As assessed by Investigator

    Time frame: Time from randomization to final assessment or until progression disease, death, discontinuation criteria approximately up to 3 years and 2 months

  2. Phase 1b: Number of Participants With Adverse Events (AEs) and Treatment-related AEs

    Time frame: Time from randomization to final assessment at end of safety follow-up visit approximately up to 3 years and 2 months

Secondary outcomes

  1. Phase 1b/Phase 2a: Duration of Response (DoR) According to RECIST 1.1 as Assessed by the Investigator

    Time frame: Time from randomization to final assessment or until progression disease, death, discontinuation criteria approximately up to 3 years and 2 months

  2. Phase 1b/Phase 2a: Progression Free Survival (PFS) According to RECIST 1.1 as Assessed by the Investigator

    Time frame: Time from randomization to final assessment or until progression disease, death, discontinuation criteria approximately up to 3 years and 2 months

  3. Phase 1b/Phase 2a: Overall survival (OS)

    Time frame: Time from randomization to final assessment or until progression disease, death, discontinuation criteria approximately up to 3 years and 2 months

  4. Phase 2a: Number of Participants With AEs and Treatment-related AEs

    Time frame: Time from randomization to final assessment at end of safety follow-up visit (approximately up to 3 years and 2 months)

07

Study locations

54 sites
  • UCLA Hematology and Oncology - Santa Monica
    Santa Monica, California 90404, United States
  • UPMC Cancer Center
    Pittsburgh, Pennsylvania 15232, United States
  • Tennessee Cancer Specialists - Biomedical Research
    Knoxville, Tennessee 37909, United States
  • The University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Millennium Research & Clinical Development
    Houston, Texas 77090, United States
  • Virginia Cancer Specialists, PC
    Fairfax, Virginia 22031, United States
  • Institut Jules Bordet - Department of Institut Jules Bordet'
    Anderlecht, Belgium
  • UZA - Oncology
    Edegem, Belgium
  • Jessa Ziekenhuis Hospital
    Hasselt, Belgium
  • Universitair Ziekenhuis Brussel - UZB
    Jette, Belgium
  • UZ Leuven
    Leuven, Belgium
  • CHU de Liège - PARENT
    Liège, Belgium
  • CHU Angers - Hôpital Larrey - Service de Pneumologie
    Angers, France
  • Centre Hospitalier Intercommunal de Créteil - Service de Pneumologie
    Créteil, France
  • CHU Limoges - Hôpital Dupuytren - Unite d'Oncologie Thoracique et Cutanée
    Limoges, France
  • Hôpital de la Timone - CPCEM CIC - Bat F 1er étage
    Marseille, France
  • Hopital Arnaud de Villeneuve - Service de Pneumologie-Addictologie
    Montpellier, France
  • Groupe Hospitalier Sud - Hôpital Haut-Lévêque - Unité d'Explorations Fonctionnelles Respiratoires
    Pessac, France
  • ICO - Site René Gauducheau - Service d'Oncologie medicale
    Saint-Herblain, France
  • Universitaetsklinikum Giessen und Marburg GmbH - Medizinische Klinik und Poliklinik III
    Giessen, Germany
  • Universitaetsklinikum Leipzig AoeR - Med. Klinik u. Poliklinik I - Abt. Pneumologie
    Leipzig, Germany
  • Sana Klinikum Offenbach GmbH - Medizinische Klinik IV
    Offenbach, Germany
  • Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi IRCCS - U.O. Oncologia Medica
    Bologna, Italy
  • IEO Istituto Europeo di Oncologia - Divisione Oncologia Medica
    Milan, Italy
  • Ospedale San Raffaele - U.O. di Oncologia Medica
    Milan, Italy
  • Istituto Nazionale Tumori Fondazione G. Pascale - Medical Oncology Thoraco-Pulmonary Department
    Naples, Italy
  • Istituto Nazionale Tumori Regina Elena IRCCS - S.C. Oncologia Medica B
    Roma, Italy
  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS - UOC Oncologia Medica
    Rome, Italy
  • Istituto Clinico Humanitas - U.O. di Oncologia Medica ed Ematologia
    Rozzano, Italy
  • National Cancer Center Hospital
    Chūōku, Japan
  • Kansai Medical University Hospital
    Hirakata-shi, Japan
  • National Cancer Center Hospital East
    Kashiwa-shi, Japan
  • Cancer Institute Hospital of JFCR
    Kōtoku, Japan
  • Kurume University Hospital
    Kurume-shi, Japan
  • Aichi Cancer Center Hospital
    Nagoya, Japan
  • Kindai University Hospital
    Osakasayama-shi, Japan
  • Kanagawa Cancer Center
    Yokohama, Japan
  • Asan Medical Center
    Seoul, South Korea
  • Samsung Medical Center
    Seoul, South Korea
  • Severance Hospital, Yonsei University Health System - Division of Infectious Diseases
    Seoul, South Korea
  • The Catholic University of Korea, Seoul St. Mary's Hospital
    Seoul, South Korea
  • Hospital Clinic de Barcelona - Servicio de Oncologia
    Barcelona, Spain
  • Hospital Universitari Vall d'Hebron - Oncology Dept.
    Barcelona, Spain
  • Hospital Universitario Reina Sofia - Dept of Oncology
    Córdoba, Spain
  • Hospital General Universitario Gregorio Marañon - Servicio de Oncologia Medica
    Madrid, Spain
  • Hospital Universitario 12 de Octubre - Servicio de Oncologia
    Madrid, Spain
  • Hospital Universitario HM Madrid Sanchinarro - Servicio de Oncologia
    Madrid, Spain
  • Hospital Universitario La Paz - Oncology Department
    Madrid, Spain
  • Hospital Universitario Ramon y Cajal - Servicio de Oncologia
    Madrid, Spain
  • Hospital Regional Universitario de Malaga - Oncology Dept
    Málaga, Spain
  • Hospital Universitario Nuestra Señora de Valme - Servicio de Oncologia
    Seville, Spain
  • Hospital Universitario Virgen del Rocio - Oncology Service
    Seville, Spain
  • Hospital Universitario Virgen Macarena - Oncology Service
    Seville, Spain
  • Hospital Universitari i Politecnic La Fe - Oncology Department
    Valencia, Spain
08

References and documents

Individual participant data

Plan to share: No — IPD will not be shared for Phase I interventional or observational studies. Further information on how to request data can be found on our website bit.ly/IPD21.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2023 to primary completion in Jul 2026, 34 months.

Of 309 industry-sponsored phase 1/2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 77. This study's 34 months is below that.

Counting every sponsor, half of 432 studies reached it within 63 months; a quarter within 42 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2023
First posted
May 31, 2023
StartActual
Sep 13, 2023
Primary completionActual
Jul 15, 2026
CompletionActual
Jul 15, 2026
Last update
Sep 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05882734
Responsible party
Sponsor
First posted
May 31, 2023
Start date
Sep 13, 2023
Primary completion
Jul 15, 2026
Completion
Jul 15, 2026
Last update
Sep 14, 2026

Study contacts

Medical Responsible
study director · Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tuvusertib · Cemiplimab

Start the discussion